Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 20/20 | 1.00 |
| ▸ | MAOA | P21397 | 4/20 | 0.74 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15136856 | 1.00 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL527033 | 1.00 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL527032 | 1.00 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL526874 | 0.99 | KDM1A (0.98) | KDM1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL526875 | 0.99 | KDM1A (0.98) | KDM1AMAOAMAOB | |
| SCHEMBL527335 | 0.89 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL7692647 | 0.89 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL527334 | 0.89 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL15136511 | 0.88 | KDM1A (0.98) | KDM1AMAOAMAOB | |
| SCHEMBL15136922 | 0.88 | KDM1A (1.00) | KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908859-B2 | Lysine demethylase inhibitors for myeloproliferative disorders | ORYZON GENOMICS, S.A. (ES) | 2018-03-06 | — | — | US | disclosed |
| US-9908859-B2 | Lysine demethylase inhibitors for myeloproliferative disorders | ORYZON GENOMICS, S.A. (ES) | 2018-03-06 | — | — | US | disclosed |
| US-20150232436-A1 | LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE DISORDERS | ORYZON GENOMICS S.A. (ES) | 2015-08-20 | — | — | US | disclosed |
| US-20150232436-A1 | LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE DISORDERS | ORYZON GENOMICS S.A. (ES) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232436-A1 | LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE DISORDERS | KDM1A, KDM1B, KDM3A | KDM1A 1/4885MAOA 523/4885MAOB 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.